Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on February 17, 2021, primarily disclosing two key pieces of information for investors. Firstly, the company announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for its drug BRUKINBRA® (zanubrutinib) for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM). This acceptance marks a significant step forward in the potential approval and commercialization of BRUKINBRA® for this new indication. The Prescription Drug User Fee Act (PDUFA) target action date for this sNDA is set for October 18, 2021, providing a clear timeline for an FDA decision. Secondly, the company also provided an update regarding its upcoming financial results announcement. BeOne Medicines expects to report its financial results for the three months and year ended December 31, 2020, on February 25, 2021. This upcoming earnings release will offer investors a look into the company's financial performance and operational progress.
Key Highlights
- 1FDA acceptance of sNDA for BRUKINBRA® (zanubrutinib) for Waldenström’s Macroglobulinemia (WM).
- 2PDUFA target action date for the BRUKINBRA® sNDA is October 18, 2021.
- 3BRUKINBRA® is indicated for adult patients with Waldenström’s Macroglobulinemia.
- 4Company to announce Q4 and Full Year 2020 financial results on February 25, 2021.
- 5The filing includes a press release detailing the FDA sNDA acceptance as an exhibit.